Early initiation of eculizumab therapy for Streptococcus pneumoniae–associated hemolytic uremic syndrome
- 16 July 2020
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (2), e28589
- https://doi.org/10.1002/pbc.28589
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndromeKidney International, 2016
- Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumabNephrology Dialysis Transplantation, 2013
- Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?Medical Hypotheses, 2013
- The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndromeNephrology Dialysis Transplantation, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2013
- Streptococcus pneumoniae-associated Hemolytic Uremic Syndrome Among Children in North AmericaThe Pediatric Infectious Disease Journal, 2011
- Streptococcus pneumoniae-associated hemolytic uremic syndromePediatric Nephrology, 2008
- Variation in the Presence of Neuraminidase Genes among Streptococcus pneumoniae Isolates with Identical Sequence TypesInfection and Immunity, 2006
- Necrotizing pneumonia in childrenActa Paediatrica, 2004
- Invasive Haemophilus influenzae type b infection in a child with familial deficiency of the beta subunit of the eighth component of complementThe Journal of Pediatrics, 1996